Sutro Biopharma (STRO) Current Deferred Revenue (2017 - 2025)

Sutro Biopharma has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $10.6 million for Q4 2025.

• Current Deferred Revenue for Q4 2025 came in at $10.6 million, down 84.86% year-over-year; the trailing twelve-month figure through Dec 2025 was $10.6 million (down 84.86% YoY), and the FY2025 annual result was $10.6 million, down 84.86% from the prior year.
• Current Deferred Revenue came in at $10.6 million for Q4 2025 at Sutro Biopharma, up from $9.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $74.0 million in Q2 2024 to a low of $5.5 million in Q4 2021.
• The 5-year median for Current Deferred Revenue is $16.3 million (2022), against an average of $24.8 million.
• Across the five-year window, Current Deferred Revenue jumped 310.09% in 2024 and plunged 87.63% in 2025, its largest moves.
• Sutro Biopharma's Current Deferred Revenue stood at $5.5 million in 2021, then soared by 204.93% to $16.8 million in 2022, then climbed by 23.31% to $20.7 million in 2023, then soared by 237.67% to $69.8 million in 2024, then tumbled by 84.86% to $10.6 million in 2025.
• The last three Current Deferred Revenue figures came in at $10.6 million (Q4 2025), $9.0 million (Q3 2025), and $12.0 million (Q2 2025), per Business Quant data.